Friday, 21 Jul 2017

You are here

Is the Jury Still Out on Triple Therapy vs. MTX + TNF inhibitor?

There are several trials that test the efficacy and safety of combination tumor necrosis factor inhibitor (TNFi) plus methotrexate against triple therapy (methotrexate plus hydroxychloroquine plus sulfasalazine) in patients with rheumatoid arthritis (RA).

Trials like TEAR, RACAT and SWEFOT have show similar and disparate results.

Researchers preformed a systematic review and network meta-analysis (NMA) of randomised controlled trials comparing TNFi-methotrexate or triple therapy. Interestingly, the primary endpoint of this analysis was an ACR 70% response (ACR70) at 6 months. 

Researchers analyzed 33 studies in patients with inadequate response to methotrexate (established RA) and 19 in patients naive to methotrexate (early RA).

Established RA - Inadequate response to MTX

Figure 2

In inadequate responders, triple therapy was associated with lower odds of achieving ACR70 at 6 months compared with TNFi-methotrexate (OR 0.35, 95% credible interval (CrI) 0.19 to 0.64). Although several secondary endpoints trended towards favoring the TNFi-methotrexate arm, there was no significant advantage for either therapy.

For those who were MTX naive, there was no advantage of either therapy with regard to the primary endpoint. Although those treated with TNFi–methotrexate were more likely to achieve ACR70 and have less X-ray progression at 2 years, this was only seen in the fixed-effects analyses and not the random-effects models. The magnitude of this effect was not felt to not be clinically relevant. 

With regard to safety, infections were lower with triple therapy than with TNFi-methotrexate (OR 0.08, 95% CrI 0.00 to 0.57). There were no differences observed between the two regimens in patients naive to methotrexate.

For those with an inadequate response to methotrexate, triple therapy was associated with 65% lower odds of achieving ACR70 at 6 months compared with TNFi-methotrexate in patients.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Withdrawal of TNF Inibitors Fails in Most RA Patients

The 12 month POET study analyzed 817 rheumatoid arthritis (RA) patients who achieved remission or low disease activity (LDAS) for ≥6 months and then randomized 2:1 to stopping or continuing their TNF inhibitor. They found that stopping TNFi had significantly negative consequences in the negative short-term, with fewer long-term negative consequences to drug cessation.

Golimumab Fails in Polyarticular Juvenile Arthritis

Treatment options for children with active polyarticular juvenile idiopathic arthritis (polyJIA) have lagged behind that seen with adult rheumatoid arthritis. Excluding new biosimilar indications, there are 9 currently approved biologics for adult RA, but only 5 of these have been approved for use in polyarticular JIA (pJIA) - abatacept, tocilizumab, etanercept, infliximab, and adalimumab.

Inflammatory Arthritis Stable after Switch to Biosimilar Infliximab

The DANBIO registrys has demonstrated that switching from infliximab (Remicade) to biosimilar CT-P13 (Inflectra in the U.S., Remsima in Europe) does not appear to have any negative effect on inflammatory arthritis disease activity, Danish researchers reported.

NOR-SWITCH Study Validates Biosimilar Use in Multiple Indications

Lancet reports the results of the NOR-SWITCH study - a trial performed in Norway as biosimilars were being introduced. This study was designed to assess the efficacy and safety of transitioning from the originator (Remicade) to the less expensive biosimilar CT-P13 (Remsima/Inflectra) in the treatment of Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis.

FDA Approves Renflexis as Second Infliximab Biosimilar

On the 21st of April, the FDA approved another infliximab biosimilar, called Renflexis (Infliximab-abda) following on the biologics license application of the South Korean manufacturer Samsung Bioepis Co. LTD.  In early developmental trials this agent was also called SB2.